866-997-4948(US-Canada Toll Free)

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 202 Pages

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 15, 8, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 28
Amarantus Bioscience Holdings Inc 28
AnGes MG Inc 28
Angionetics Inc 29
Ascendia Pharmaceuticals LLC 29
AstraZeneca Plc 30
Athera Biotechnologies AB 30
Bayer AG 31
Biscayne Pharmaceuticals Inc 31
Capricor Therapeutics Inc 32
CardioVascular BioTherapeutics Inc 32
CSL Ltd 33
Gilead Sciences Inc 33
Human Stem Cells Institute 34
Idorsia Ltd 34
Juventas Therapeutics Inc 35
Lee's Pharmaceutical Holdings Ltd 35
LipimetiX Development Inc 36
Livzon Pharmaceutical Group Inc 36
Lonestar Heart Inc 37
MedImmune LLC 37
Merck & Co Inc 38
Nuo Therapeutics Inc 39
Pfizer Inc 39
Proteon Therapeutics Inc 40
Resverlogix Corp 40
Tasly Pharmaceutical Group Co Ltd 40
The Medicines Company 41
Verseon Corp 42
VESSL Therapeutics Ltd 42
ViroMed Co Ltd 43
XyloCor Therapeutics Inc 43
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 44
ACT-246475 - Drug Profile 44
AEM-28 - Drug Profile 45
AEM-2802 - Drug Profile 47
ALD-201 - Drug Profile 48
alferminogene tadenovec - Drug Profile 50
alprostadil - Drug Profile 55
AMRS-001 - Drug Profile 57
anacetrapib - Drug Profile 66
apabetalone - Drug Profile 69
APT-402 - Drug Profile 82
AZD-5069 - Drug Profile 83
AZD-5718 - Drug Profile 85
BAT-2094 - Drug Profile 86
beperminogene perplasmid - Drug Profile 87
BIS-5409 - Drug Profile 92
bivalirudin trifluoroacetate - Drug Profile 93
cangrelor tetrasodium - Drug Profile 94
CAP-1002 - Drug Profile 98
CAP-2003 - Drug Profile 105
clopidogrel bisulphate - Drug Profile 107
COR-2 - Drug Profile 108
Cryocell - Drug Profile 109
CSL-112 - Drug Profile 110
CVBT-141H - Drug Profile 112
dalcetrapib - Drug Profile 113
Gemacell - Drug Profile 117
JVS-100 - Drug Profile 118
MEDI-6012 - Drug Profile 123
MultiGeneAngio - Drug Profile 125
MZ-004 - Drug Profile 126
Neovasculgen - Drug Profile 128
PC-mAb - Drug Profile 129
PF-06282999 - Drug Profile 132
PMC-6 - Drug Profile 133
PR-15 - Drug Profile 134
Proteins for Ischemic Heart Disease - Drug Profile 136
ranolazine ER - Drug Profile 137
Recombinant Protein for Cardiovascular Diseases - Drug Profile 140
Rejuveinix - Drug Profile 141
rivaroxaban - Drug Profile 142
Small Molecules for Ischemic Heart Disease - Drug Profile 159
Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 160
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 161
TSL-0202 - Drug Profile 163
vericiguat - Drug Profile 164
VM-202 - Drug Profile 166
vonapanitase - Drug Profile 170
XC-001 - Drug Profile 176
Xcel-hCardP - Drug Profile 177
Xcel-hCM - Drug Profile 178
ZK-001 - Drug Profile 179
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 181
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 185
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 187
Featured News & Press Releases 187
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198

List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Angionetics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2017 (Contd..3), H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *